Tech Skeptics, Anti-Semitism, Pain Profiteering, and Pharma Triumphs

In the realm of technology, a recent podcast hosted by Derrick Broze of The Conscious Resistance brought together journalists and researchers to discuss public skepticism towards Elon Musk. The conversation, featuring Whitney Webb, James Corbett, Jason Bermas, and Ryan Cristián, revolved around the themes of technocracy and transhumanism.

In international news, several prominent news outlets, including The New York Times and The Financial Times, have published articles portraying Russia and China as anti-Semitic and anti-Israel. This portrayal comes amidst the US’s attempts to undermine Moscow and Beijing’s efforts to play a larger role in the Palestine-Israel peace process. The US’s strategy appears to be to maintain its monopoly over the peace process by discrediting Russia and China’s involvement through accusations of anti-Semitism and anti-Israel sentiment. However, the global majority seems ready for a more balanced approach, as indicated by increasingly lopsided UN votes that isolate the US.

Turning to the medical industry, a recent text highlighted the prioritization of financial gain in the pain industry and the issue of profiteering during the COVID-19 pandemic. The text discussed the risks and limitations associated with NSAIDs and opioids, the suppression of potential cures that could threaten profitable markets, and instances of corruption within the medical industry. The text also emphasized the drawbacks of relying solely on MRI findings for assessing back pain and introduced alternative treatments.

In pharmaceutical news, AstraZeneca has increased its earnings forecasts for the year, with surging sales of cancer medicines offsetting plummeting sales of COVID vaccines. The company’s revenues were largely driven by a 17% increase in sales of cancer drugs, particularly its cancer immunotherapy drug Imfinzi. Despite a 65% drop in sales from the firm’s vaccine & immune therapies division, AstraZeneca’s sales increased in all regions worldwide, apart from China. The company attributed the drop in sales from China to a reduction in promotional activities due to an anti-corruption campaign led by Chinese health authorities. AstraZeneca also announced an exclusive licensing agreement with Shanghai company Eccogene to develop and sell its experimental ECC5004 drug as a treatment for obesity.

This is a companion discussion topic for the original entry at